Menu
Submit Data
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Back to Studies

Semaglutide

Ozempic, Rybelsus, Wegovy

Quick Stats
Studies 78
Trials 100
Overview Studies Clinical Trials
Score 3
2025 pubmed

The unseen risk of Ozempic: NAION and vision damage.

Saleem. Noor Ul Ain NUA; Khan. Mishaim M; Tague. Christian C; Akilimali. Aymar A

View on DOI View Original Source

Key Findings

  • Semaglutide is widely used off‑label for weight loss due to its appetite‑suppressing effects.
  • Clinical data report NAION in 6.7% of overweight participants and 8.9% of diabetic participants taking semaglutide.
  • The FDA has warned about counterfeit/compounded versions and highlighted concerns about unsupervised use.

Practical Outcomes

  • If you’re using semaglutide for weight loss or metabolic health, watch for sudden vision changes and get regular eye exams. Consider discussing the eye‑risk with a healthcare professional before starting, especially if you have existing vascular or eye issues. Stick to FDA‑approved products and avoid unverified compounding pharmacies.

Summary

A recent look at semaglutide (Ozempic/Wegovy) shows that while it helps lower blood sugar and cut weight, it may also raise the chance of a serious eye problem called non‑arteritic anterior ischemic optic neuropathy (NAION), with about 6‑9% of users experiencing it in studies.

Abstract

Ozempic (semaglutide) was first authorized to treat type 2 diabetes, but because of its appetite-suppressing properties, it has become popular off-label for weight loss. According to clinical investigations, GLP-1 significantly decreases blood sugar and helps people lose weight. Approximately 15 million persons in the United States are currently taking GLP-1 drugs. Off-label use is becoming more common, which raises worries about potential health hazards and significant side effects such as non-arteritic anterior ischemic optic neuropathy (NAION). According to a study, 6.7% of people who were overweight and 8.9% of those with diabetes who took semaglutide had NAION. The FDA issued a warning regarding counterfeit and compounded products while approving semaglutide for weight loss under the Wegovy<sup>&#xae;</sup> brand. Unsupervised usage and problems with diabetes accessibility raise ethical questions.

Study Information

Provider

pubmed

Year

2025

Date

2025-10-20T00:00:00.000Z

DOI

10.1097/ms9.0000000000004149